Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord(R) as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.
The miracle of stem cells changes the life of a little boy from the Eastern Shore.
Adam May has the amazing story of a mother and the choice she made moments after her son was born.
Read the full article and watch the video on CBS Baltimore
Dr Roger Dainty, the UK director of Europe’s first accredited private family stem cell bank, visited recently Sofia to celebrate the five-year anniversary and co-operation with the Bulgarian partner, Medical Centre Aphrodite.
Professor Suzanne Watt discusses improving cord blood transplant outcomes by understanding the bone marrow niche.
DUCORD is approved for use in hematopoietic stem cell transplantation for patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
The first clinical trials for stem cell based voice box transplants could begin as soon as 2013, according to leading expert Professor Martin Birchall speaking at the UK National Stem Cell Network annual science meeting today in York.
New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells’ potential to treat inflammatory bowel disease (IBD).
